A Phase 4 interventional study of Ferinject (ferric carboxymaltose) and Placebo (saline) in Iron Deficiency and Chronic Heart Failure, sponsored by Vifor Pharma. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-18.
Sponsored by Vifor Pharma · Phase 4, Interventional, and Treatment
The purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 304 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Vifor Pharma is the lead sponsor of 21 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Ferinject (ferric carboxymaltose)
Drug: Placebo (saline)
Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
Subjects will receive Placebo (saline) intravenously on Day 0
Change in six minute walk test from baseline to week 24
Time frame: 24 weeks
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vifor Pharma